Business Wire | June 6, 2017
Abreos Biosciences, a San Diego-based biotech company and a leader in the precision dosing of biological therapeutics, is pleased to announce that it has completed a new investment round. The funding came from existing investors as well as new investor TLP Investment Partners LLC and its affiliates.
The unique Abreos Veritope technology platform allows for the selective monitoring of therapeutic antibody drugs, whether brand name or biosimilars. By monitoring the levels of these therapies, clinicians can optimize therapeutic dose and timing to help achieve optimal response to these expensive therapies.
“Biologics are among the most powerful therapeutics available for many serious diseases, yet many patients are under- or over-dosed due to the lack of simple monitoring tests that can tell how much drug a patient has in their blood. We are hoping to make personalized, precision dosing a reality for these patients,” said Bradley Messmer, Ph.D., CEO and founder of Abreos.